Abstract Case Report
IntroductIon
Conidiobolus coronatus is a recognised human pathogen that causes subcutaneous fungal infections, often on the face of immunocompetent patients from tropical and subtropical regions, including India. [1] [2] [3] However, C. coronatus infections in first-line antiretroviral therapy (ART)-resistant HIV-infected individuals, particularly those with rhinoentomophthoromycosis, have not been previously reported. Most cases of C. coronatus-related rhinoentomophthoromycosis in immunocompetent and immunocompromised HIV-negative patients have been successfully treated with antifungal drugs such as ketoconazole, fluconazole and itraconazole. [4, 5] Immunocompromised hosts, particularly those with HIV infection or AIDS, are vulnerable to variety of fungal infections and experience poor therapeutic responses. [6] [7] [8] [9] [10] Resistance to first-line ART is an emerging issue, particularly in cases of treatment noncompliance. [11] [12] [13] This report describes a case of itraconazole-nonresponsive rhinoentomophthoromycosis in an HIV-infected patient with first-line ART drug resistance and the unique therapeutic approach utilised to successfully manage the case.
casE rEport
A 32-year-old HIV-1-infected man presented with painless left nasal mucosal swelling and erythema causing respiratory difficulty. He stated that these signs and symptoms were present for approximately 9 months. On investigation, it was determined that the probable underlying cause of the infection was a traumatic injury to the nose by rotten wood the onset of his symptoms. He was afebrile and had no signs of oral candidiasis, regional lymphadenopathy, diarrhea or any other signs of gastrointestinal infections. He had no history of headaches or meningitis, and no other symptoms were elicited during the investigation.
haemodynamically stable. The patient's vision was normal, and no other complications beyond the affected area were noted. A computed tomography scan of the paranasal sinuses confirmed middle and inferior turbinate hypertrophy with adhesions, leading to blockage of the nasal pathway [ Figure 2a and b]. A 4-mm skin biopsy was taken from the nasal mucosal mass with the utmost precaution. Histological examination of the biopsied specimen stained with Hematoxylin & Eosin stain revealed acanthosis with dense neutrophilic, lymphocytic and eosinophilic infiltration throughout the dermis [ Figure 3a] . Fine needle aspiration cytology of the inferior turbinate mass revealed a granulomatous infiltrate containing large numbers of lymphocytes, macrophages, giant cells and epithelioid cells [ Figure 3b ]. No fungal elements were observed in periodic acid-Schiff-stained tissue sections.
Further, the processed specimen was inoculated and incubated at both room temperature and at 37°C, on Sabouraud's dextrose agar (SDA) medium.
Diagnosis
Fungal growth with small satellite colonies at the periphery was only visible on SDA medium (at 25°C) within 4 days [ Figure  4 ]. Repeat biopsy specimens and a minimum of three sets of processed cultured specimens demonstrated consistent fungal growth on SDA. The mature obverse side of the colonies were tan to brown in colour within 4 days due to aging, and the reverse side was white in colour. A lactophenol wet mount of the fungus on the SDA plate revealed unbranched sporangiophore-bearing sporangiole at the tip and typical pyriform conidia with prominent papillae. A comparison with the macroscopic and microscopic features of a standard strain of C. coronatus (ATCC PTA-4132) confirmed the isolated fungus to be C. coronatus. Confirmation of C. coronatus using uncommon molecular tests such as direct DNA sequencing of internal transcribed spacer and D1/D2 regions of rDNA and serum levels for drug concentration was out of question because of limited health insurance and patient's personal financial condition.
Based on the clinical presentation and mycological results, the patient was started on oral itraconazole at a twice-daily dose of 200 mg and a saturated potassium iodide solution at an initial dose of 5 drops thrice daily, gradually increasing to a maximum of 40 drops per day. Despite proper adherence to first-line ART (Zidovudine (AZT) + Lamivudine (3TC) + Nevirapine (NVP)) and itraconazole, the patient exhibited worsening of respiratory difficulty due to increased nasal mucosal swelling and obstruction. In addition, the development of weakness, dyspnea on exertion and losses of appetite and weight suggested first-line ART failure. The viral load and CD4+ count test results confirmed this suspicion. Based on the findings, significantly lowered CD4+ count (50 cells/mm 3 ), an increased HIV-1 RNA viral load of 50,000 copies/ml, clinical symptoms and failure to respond to itraconazole, the patient was immediately switched to second-line ART due to his critical condition. The patient was started on ART that included 300 mg of tenofovir, 300 mg of lamivudine, 300 mg of atazanavir and 100 mg of ritonavir once daily along with the continuation of oral itraconazole at 200 mg/day and saturated potassium iodide drops. 
dIscussIon
Before the advent of highly active ART (HAART) in 1996, infection management in AIDS patients was a major challenge, with consequent increases in mortality rates. With HAART therapy or newly improved antiretroviral drugs, it has been possible to control HIV viral replication with the beneficial effect of increasing the numbers of CD4+ T cells, which assist antifungal drugs in the clearance of chronic fungal infections. [14] [15] [16] [17] This particular case highlights the occurrence of C. coronatus-related rhinoentomophthoromycosis in an AIDS patient who initially exhibited therapeutic failure due to an apparent underlying resistance to ART. The histopathological patterns of such infections vary in AIDS patients as a result of severe T cell population depletion with deficiency. Overall, the therapeutic response to or clearance of fungal infections is more rapid in immunocompetent individuals than in immunocompromised patients. For example, cutaneous infections in immunocompetent patients induce granulomatousreactions against fewer numbers of encapsulated yeasts,whereas AIDS patients normally exhibit heavy colonisation of encapsulated yeasts, as seen in gelatinous stroma. [4] Overall, the therapeutic response to or clearance of fungal infections is more rapid in immunocompetent individuals than in immunocompromised patients.
In cases of C. coronatus infections in immunocompetent and immunocompromised individuals, the subsequent histopathological patterns remain the same. The cutaneous tissue response to C. coronatus in both immunocompromised HIV-seronegative patients and immunocompetent patients typically reveals the presence of hyphal filaments and a granulomatous reaction encircled by eosinophilic deposits, known as the Splendore-Hoeppli phenomenon. [18, 19] In our studies, no typical hyphal filaments were observed in the dermal tissue sections. Other epidermal cellular responses included mild-to-moderate acanthosis, and the dermis exhibited dense neutrophilic, lymphocytic and eosinophilic infiltration. This histopathological pattern varies somewhat from previously published reports of C. coronatus infections in HIV-negative individuals. [1] [2] [3] 20, 21] Repeated cultured biopsy specimens demonstrated the consistent growth of C. coronatus. Whether this atypical presentation of C. coronatus in the patient-derived tissue sections was due to the extremely low CD4+ count and heavy viral load or to other unknown reasons remains unclear. More investigations will be needed in similar case scenarios.
conclusIon
To the best of our knowledge, there have not been any published reports of C. coronatus-related rhinoentomophthoromycosis infection, particularly in HIV/AIDS patients (resistant to first line ART). It is noteworthy that second-line ART augmented the antifungal activity of itraconazole against a C. coronatusassociated subcutaneous infection in an HIV-infected (AIDS) patient. The gradual resolution of the infected nasal lesion may be attributable to a reconstituted T cell (CD4+) immune response and dramatically reduced viral load. This study indicates how viral load testing can be used as a guide for clinical decisions, specifically on when to switch to second-line treatment and on how to optimize the duration of first-line treatment regimen. Additional observations are needed to evaluate the role of second-line ART-associated immune restoration and its plausible catalytic effect on antifungal drug (itraconazole) activity against C. coronatus in HIV-infected patients.
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